The influence of thrombophilic factors on the incidence of deep vein thrombosis and pregnancy complications;Der einfluss thrombophiler faktoren auf thromboembolische und andere schwangerschaftskomplikationen

Zeitschrift fur Geburtshilfe und Neonatologie

Volumn 205, Issue 4, 2001, Pages 128-136

  Heilmann, L ^a   Tempelhoff, F G V ^a   Gerhold, S ^a   Rath, W ^b  

^a Gesundheits und Pflegezentrum Russelsheim   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Deep vein thrombosis; Preeclampsia; Pregnancy; Recurrent abortion; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN;

COMORBIDITY; DEEP VEIN THROMBOSIS; FEMALE; FETUS DEATH; FETUS GROWTH; HIGH RISK PREGNANCY; HUMAN; INCIDENCE; LUNG EMBOLISM; PREECLAMPSIA; PREGNANCY COMPLICATION; RECURRENT ABORTION; REVIEW; SIDE EFFECT; THROMBOPHILIA;

EID: 0034862148     PISSN: 09482393     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-16821     Document Type: Review

References (99)

1. Pregnancy complications in women with recurrent miscarriage and antiphospholipid antibodies treated with aspirin and heparin
2. First trimester repeated abortion is not associated with activated protein C resistance
3. Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects
4. Antiphospholipid antibodies in pregnancy
5. Arg 506-GLn mutation in factor V and risk of thrombosis during pregnancy
6. Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience
7. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause
8. Pregnancy complicated by the antiphospholipid syndrome: Outcomes with intravenous immunoglobulin therapy
9. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S
10. Pregnancy and congenital deficiency in antithrombin m or protein C
11. Familiar thrombophilia and activated protein C resistane - Thrombotic risk in pregnancy?
12. Treatment of antiphospholipid syndrome in pregnancy
13. Thrombotic risk during pregnancy and puerperium in women with APC resistence - Effective subcutaneous heparin prophylaxis in pregnant patients
14. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies
15. Prothrombin 20210G > A mutation analysis in Caucasian women with early first trimester pregnancy loss
16. Underlying disorders associated with severe early onset preeclampsia
17. Thromboembolic disease
18. The role of four coagulation genes in thrombosis during pregnancy: Factor V Leiden, Prothrombin 20210, MTHFR, ACE
19. The factor V Leiden mutation may predispose women to severe preeclampsia
20. Factor V Leiden and prothrombin 620210A mutations but not methylentetrahydrofolat reductase C677T are associated with recurrent miscarriage
21. Frequency of pregnancy related thromboembolism in anticoagulant factor deficient women: Implications for prophylaxis
22. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium
23. Incidence, clinical characteristics and timing of objectively diagnosed venous thromboembolism during pregnancy
24. Thromboembolism and pregnancy
25. G to A 20210 Prothrombin polymorphism and venous thrombosis: Simple association or causal relationship?
26. Factor V Leiden, C > T MTHFR Polymorphismus and genetic susceptibility to preeclampsia
27. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria
28. Genetic susceptibility to pregnancy related to venous thromboembolism: Roles for factor V Leiden, prothrombin G20210A and methylene tetrahydrofolate reductase C677T mutations
29. Faktor V Leiden is associated with repeated and recurrent fetal losses
30. Obstetric outcome in antiphospholipid syndrome
31. Antiphospholipid antibodies and thrombosis
32. Thrombosis prophylaxis in obstetric and gynecology
33. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynecology
34. Thrombosis in pregnancy: Malemal and fetal issues
35. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy
36. Antiphospholipid-antibodies and other thrombophilic defects in patients with a history of early onset severe preeclampsia or HELLP-syndrome
37. Antithrombotic therapy in high risk pregnancy
38. Venenthrombosen und lungenembolien in der schwangerschaft und im wochenbett
39. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives
40. Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antithrombin
41. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use. Prevalence of factor V Leiden
42. Screening for heritable thrombophilic risk factors in a recurrent miscarriage population
43. β2-Glycoprotein I-dependent anticardiolipid antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women
44. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome
45. Hypercoagulability and recurrent abortion
46. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelet syndrome
47. A retrospective review of 61 patients with antiphospholipid syndrome
48. Increased frequency of genetic thrombophilia in women with complications of pregnancy
49. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low dose aspirin is superior to low dose aspirin alone
50. Hypercoagulable stete mutation analysis in white patients with early first trimester recurrent pregnancy loss
51. Obstetric performance in patients with the lupus anticoagulant and/or anticardiolipid antibodies
52. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss
53. A study of sixty pregnancies in patients with the antiphospholipid syndrome
54. Preeclampsia is associated with reduced response to activated protein C
55. Prednison does not prevent recurrent fetal death in women with antiphospholipid antibody
56. Lupus anticoagulant and pregnancy
57. Antiphospholipid antibodies in predicting adverse pregnancy outcome
58. Venous thrombembolic diseaese in obstetrics and gynaecology. The Scottish experience
59. Risk factors for pregnancy associated venous thromboembolism
60. Usefulness of screening for congenital or acquired hemostasis abnormalities in women with previous complicated pregnancies
61. Prevalence of FVL is not increased in women with recurrent miscarriage
62. Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation
63. Prospective evaluation of the risk conferred by FVL and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy
64. The PAI-1 4G/4G genotype is a risk factor for venous thrombosis carriers of the FVG1691A mutation
65. Thrombomodulin gene variations and thromboembolic disease
66. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies
67. Incidence of metabolic and hemostatic variables in 72 women with pregnancy induced hypertension
68. Normal prevalence of the G20210A prothrombin gene mutation in women with recurrent miscarriage
69. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
70. Increased fetal loss in women with heritable thrombophilia
71. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
72. Second trimester pregnancy loss is associated with activated protein C resistance
73. Reduction of annexin V (placental anticoagulant protein I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion
74. Folic acid and homocysteine metabolic defects and the risk of placental abruption, preeclampsia and spontaneous pregnancy loss: A systematic review
75. Recurrent adverse pregnancy outcome and antiphospholipid antibodies
76. Influence of antiphospholipid antibody titer, prior pregnancy losses and treatment
77. Factor V Leiden mutation is a risk factor for recurrent pregnancy loss
78. Risk factors for venous thrombotic disease
79. Thromboembolic disease associated with pregnancy: An 11 year review
80. Thrombophilia is common in women with pregnancy loss associated with late pregnancy wastage
81. Clinical consequences of antiphospholipid antibodies: An historic cohort study
82. The impact of the factor V Leiden mutation on pregnancy
83. Factor V Leiden mutation and unrecognized cause of hemiplegic cerebral palsy, neonatal stroke and placental thrombosis
84. Obstetrical complications associated with antiphospholipid antibodies
85. Normal fetal growth in women with anti-phospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG)
86. Factor V Leiden: Should we screen oral contraceptive users and pregnant women?
87. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia
88. Risk of thrombosis during pregnancy and postpartum in hereditary thrombophilia
89. Plasma total homocysteineq and previous pregnancies: The Hordaland Homocysteine Study
90. Thrombophilia in pregnancy
91. Changes in homocystein levels during normal pregnancy
92. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome
93. Prevalence of factor V G1691A mutation and prothmmbin 20210A polymorphism in women with habitual abortions
94. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy
95. Activated protein C resistance and FVL mutation can be associated with first as well as second trimester recurrent pregnancy loss